{"gene":"HAS3","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2013,"finding":"HAS3 produces hyaluronan at high speed even with minimum UDP-sugar substrate content, in contrast to HAS1 (which requires ~10-fold higher UDP-GlcNAc) and HAS2 (intermediate requirement). Transfected HAS3 consumed enough UDP-sugars to reduce their cellular content in COS-1 cells.","method":"Transfection of COS-1 cells with human HAS1-3 isoenzymes; glucosamine supplementation and glucose deprivation to manipulate UDP-sugar levels; measurement of hyaluronan secretion and UDP-sugar content","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with substrate manipulation in transfected cells, multiple orthogonal conditions tested, single lab","pmids":["23303191"],"is_preprint":false},{"year":2016,"finding":"HAS3 undergoes rapid recycling between the plasma membrane and endosomes, regulated by cytosolic UDP-GlcNAc and UDP-GlcUA levels. UDP-GlcNAc surplus suppresses HAS3 endocytosis and lysosomal decay, retaining HAS3 at the plasma membrane and stimulating hyaluronan synthesis and HAS3 shedding in extracellular vesicles. UDP-GlcNAc concentration also controls the level of O-GlcNAc modification of HAS3; increasing O-GlcNAcylation reproduces the effects of UDP-GlcNAc surplus on HAS3 trafficking, while suppression shows opposite effects.","method":"Live-cell fluorescence microscopy, endocytosis assays, O-GlcNAc inhibition/enhancement pharmacology, extracellular vesicle isolation and characterization in HAS3-expressing cells","journal":"Cellular and molecular life sciences : CMLS","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (live imaging, pharmacological manipulation, vesicle shedding assays), single lab","pmids":["26883802"],"is_preprint":false},{"year":2014,"finding":"Rab10 GTPase controls HAS3 endocytic traffic: Rab10 colocalizes with HAS3 in intracellular vesicles and co-immunoprecipitates with HAS3 from endosomal fractions. Rab10 silencing increases plasma membrane residence of HAS3, resulting in increased HA secretion and enlarged cell-surface HA coat; Rab10 overexpression suppresses HA synthesis. Rab10 silencing blocks retrograde traffic of HAS3 from plasma membrane to early endosomes. The enlarged HA coat impairs cell adhesion to type I collagen (adhesion recovered after hyaluronidase treatment).","method":"Co-immunoprecipitation from endosomal fractions, Rab10 siRNA silencing, Rab10 overexpression, live fluorescence microscopy, HA coat measurement, cell adhesion assay with hyaluronidase rescue","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP from endosomes plus gain/loss-of-function with defined cellular phenotype and hyaluronidase rescue, single lab, multiple orthogonal methods","pmids":["24509846"],"is_preprint":false},{"year":2015,"finding":"HAS3 forms homomeric complexes with itself and heteromeric complexes with HAS1 and HAS2. These complexes are present in both the Golgi apparatus and the plasma membrane. Interaction occurs mainly via the N-terminal 86-amino acid domain, with additional binding sites in the C-terminal region. HAS3 homomers show the highest synthetic activity among HAS homomers. HAS1 transfection reduced HA synthesis driven by HAS2 and HAS3, indicating functional cooperation.","method":"FRET in live cells (flow cytometric FRET and acceptor photobleaching FRET microscopy), proximity ligation assay with endogenous HAS antibodies, C-terminal deletion mutants to map interaction domains","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal PLA for endogenous proteins plus FRET with deletion mapping, multiple orthogonal methods, single lab","pmids":["25795779"],"is_preprint":false},{"year":2015,"finding":"GFP-HAS3 overexpression induces the formation of long, slender plasma membrane protrusions that are maintained by ongoing hyaluronan synthesis; hyaluronidase digestion causes immediate GFP-HAS3 exit from protrusions and protrusion collapse, indicating that the extracellular hyaluronan chain retains HAS3 in the plasma membrane. These protrusions share cytoskeletal features with filopodia (fascin, Myo10 positive) but do not require substratum attachment.","method":"GFP-HAS3 overexpression in MCF-7 cells, live fluorescence microscopy, hyaluronidase treatment, immunostaining of cytoskeletal markers (villin, ezrin, espin, fascin, Myo10), ultrastructural comparison with rat peritoneal mesothelial cells","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — live imaging plus hyaluronidase rescue and cytoskeletal marker analysis, single lab, single study","pmids":["26162854"],"is_preprint":false},{"year":2015,"finding":"Correlative light and electron microscopy (CLEM) revealed that GFP-HAS3 localizes to and induces dorsal plasma membrane ruffles, not only elongated protrusions.","method":"Correlative light and electron microscopy (CLEM) of GFP-HAS3 expressing cells","journal":"International journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct high-resolution structural localization by CLEM, single lab, single method","pmids":["26448759"],"is_preprint":false},{"year":2011,"finding":"HAS3 overexpression in MDCK cells causes accumulation of hyaluronan at apical and basolateral membrane domains, impairing cell-cell junction formation and epithelial barrier function. In 3D cyst cultures, HAS3-induced HA accumulation results in aberrant mitotic spindle orientation and multiple small lumina instead of a single lumen.","method":"Stable overexpression of GFP-HAS3 in MDCK cells, 3D cyst culture, fluorescence microscopy of cell-cell junctions and mitotic spindles, barrier function assay","journal":"Histochemistry and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — defined cellular phenotypes with GFP-HAS3 overexpression in 3D culture, multiple readouts, single lab","pmids":["22159845"],"is_preprint":false},{"year":2014,"finding":"Has3 knockout mice show the greatest reduction of HA in the hippocampus among Has knockout models, with a ~40% reduction in extracellular space (ECS) volume specifically in the CA1 stratum pyramidale, increased cell packing, reduced molecular diffusion through ECS, spontaneous epileptiform activity in CA1 pyramidal neurons, and susceptibility to seizures. Osmotic manipulation experiments provided causal evidence linking reduced ECS volume to epileptiform activity.","method":"Has3-/- knockout mice; real-time iontophoretic measurement of ECS volume; fluorescent marker diffusion imaging; electrophysiology in brain slices; osmotic manipulation experiments","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal in vivo and ex vivo methods (ECS measurement, electrophysiology, histology, osmotic rescue), well-controlled study","pmids":["24790187"],"is_preprint":false},{"year":2015,"finding":"HAS3 overexpression in MV3 melanoma cells expands the cell-surface HA coat and decreases cell adhesion, migration, and proliferation (G1/G0 arrest). Migration inhibition was reversed by hyaluronidase or HA oligosaccharide receptor blocking, indicating HA-receptor-dependent effect. Proliferation inhibition was receptor-independent. HAS3 overexpression decreased ERK1/2 phosphorylation, implicating MAP-kinase signaling.","method":"Inducible HAS3 expression in MV3 cells; hyaluronidase treatment and HA oligosaccharide competitive blocking; cell cycle analysis; ERK1/2 phosphorylation by western blot; migration and adhesion assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — loss-of-function/gain-of-function with defined phenotypic readouts and rescue experiments, single lab","pmids":["26222208"],"is_preprint":false},{"year":2013,"finding":"Lutein (a non-provitamin A carotenoid) activates retinoic acid receptor (RAR) signaling to upregulate HAS3 gene expression and hyaluronan synthesis in human keratinocytes. The RAR antagonist LE540 abolished lutein-dependent hyaluronan synthesis. Citral (retinal dehydrogenase inhibitor) decreased lutein-stimulated synthesis, suggesting lutein metabolites (not lutein itself) act as RAR ligands.","method":"RAR antagonist (LE540) treatment, retinal dehydrogenase inhibitor (citral) treatment, RARE-driven reporter assay, qPCR of HAS3 mRNA, HA synthesis measurement in cultured human keratinocytes","journal":"Bioscience, biotechnology, and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological pathway dissection with reporter assay, multiple inhibitors tested, single lab","pmids":["23748778"],"is_preprint":false},{"year":2015,"finding":"The HAS3 gene promoter lacks a canonical TATA box but contains GC boxes with functional Sp1 binding sites. A proximal Sp1 binding site is essential for robust proximal promoter activity, and a core MTE (motif ten element) is required for basic core promoter activity. Two novel transcriptional variants with distinct transcription start sites were identified.","method":"5' RACE, progressive deletion analysis of the 5'-flanking region, site-directed mutagenesis of Sp1 and MTE sites, luciferase reporter assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — site-directed mutagenesis with reporter assays establishing functional promoter elements, single lab","pmids":["25843802"],"is_preprint":false},{"year":2019,"finding":"HAS3-overexpressing melanoma cells shed extracellular vesicles (EVs) carrying HAS3, hyaluronan, and IHH (Indian Hedgehog). These EVs bind target cells via CD44-HA interaction and activate the hedgehog signaling cascade in target cells, leading to c-Myc upregulation and increased claspin expression, resulting in enhanced proliferation and epithelial-to-mesenchymal transition.","method":"GFP-HAS3 overexpression in metastatic melanoma cells; EV isolation and characterization; CD44-blocking experiments; treatment of recipient keratinocytes and melanoma cells; hedgehog pathway reporter assays; c-Myc and claspin western blot; IHH proteomics identification in EVs","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple orthogonal methods (EV characterization, CD44 blocking, pathway reporters, western blot), single lab","pmids":["31820036"],"is_preprint":false},{"year":2020,"finding":"miR-10b and miR-29a directly repress HAS3 expression by binding its 3'UTR. HAS3 inhibits cell proliferation and migration in LNCaP prostate cancer cells, while increasing colony-forming ability. During neuroendocrine transdifferentiation, miR-10b and miR-29a are induced and HAS3 is repressed.","method":"Reporter gene assays (3'UTR luciferase), western blotting, qRT-PCR, cell proliferation and migration assays with HAS3 modulation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — 3'UTR reporter assay plus protein-level validation and functional cellular assays, single lab","pmids":["31948751"],"is_preprint":false},{"year":2024,"finding":"FOSL1 transcriptionally regulates HAS3 expression; melatonin suppresses FOSL1 and thereby downregulates HAS3, reducing HA accumulation and inhibiting cancer stem cell properties (CD44 expression, tumor-initiating frequency) in head and neck squamous cell carcinoma.","method":"FOSL1 knockdown and overexpression, HAS3 mRNA/protein measurement, HA ELISA, tumor sphere formation assays, in vivo tumor-initiating frequency assay, ChIP or transcription factor binding analysis implied","journal":"Journal of pineal research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — gain/loss-of-function for FOSL1 with HAS3 as readout plus in vivo validation, single lab","pmids":["38402581"],"is_preprint":false},{"year":2022,"finding":"HAS3 is expressed in airway intermediate progenitor cells (IPCs) and its delayed upregulation (after HAS2) promotes the transition of suprabasal IPCs to a goblet cell fate during IL-4-induced allergic airway inflammation. Inhibition of HA synthesis by 4-methylumbelliferone suppressed IL-4-induced goblet cell hyperplasia.","method":"IL-4 stimulation of primary human nasal epithelial cells; HAS2/HAS3 mRNA and protein analysis; 4-methylumbelliferone inhibition; house dust mite murine AR model with MU treatment; cell-type-specific expression analysis","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological inhibition with defined cellular phenotype in vitro and in vivo, cell-type resolved expression, single lab","pmids":["35679095"],"is_preprint":false},{"year":2022,"finding":"GFP-HAS3 overexpression in MCF7 breast cancer cells promotes shedding of morphologically diverse extracellular vesicles, as characterized by multiple high-resolution imaging modalities in situ in monolayer and 3D cultures.","method":"Stable GFP-HAS3 expression in MCF7 cells; electron microscopy, confocal microscopy, cryo-EM, and other high-resolution imaging of EVs in situ","journal":"European journal of cell biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — morphological characterization only, no biochemical or functional mechanistic dissection, single lab","pmids":["35569384"],"is_preprint":false}],"current_model":"HAS3 is a plasma membrane-localized hyaluronan synthase that synthesizes hyaluronan from UDP-GlcNAc and UDP-GlcUA with high catalytic efficiency even at low substrate concentrations; it undergoes Rab10-mediated endocytic recycling between the plasma membrane and endosomes, with its surface residence—and thus HA synthesis—controlled by UDP-GlcNAc levels and O-GlcNAcylation; it forms homo- and heteromeric complexes with HAS1/HAS2 primarily via its N-terminal domain; its synthesis product maintains HAS3 in plasma membrane protrusions (filopodia-like structures and dorsal ruffles); it is transcriptionally regulated by EGF/TGF-β, retinoic acid receptor signaling via FOSL1 and Sp1, and post-transcriptionally by miR-29a and miR-10b; and it regulates extracellular space volume in the brain, cell adhesion via ERK signaling, mitotic spindle orientation in epithelia, and intercellular communication through EV shedding carrying IHH to activate hedgehog signaling in recipient cells."},"narrative":{"mechanistic_narrative":"HAS3 is a plasma membrane hyaluronan synthase that drives extracellular matrix and cell-surface hyaluronan (HA) production, displaying the highest catalytic efficiency among the HAS isoenzymes and synthesizing HA rapidly even at low UDP-sugar substrate concentrations [PMID:23303191, PMID:25795779]. Its synthetic output is governed by trafficking: HAS3 cycles rapidly between the plasma membrane and endosomes, and surplus cytosolic UDP-GlcNAc—acting in part through O-GlcNAcylation of HAS3—suppresses its endocytosis and lysosomal turnover, retaining the enzyme at the cell surface to stimulate HA synthesis and HAS3 shedding in extracellular vesicles [PMID:26883802]. This retrograde endocytic traffic is controlled by the Rab10 GTPase, which binds HAS3 in endosomes; loss of Rab10 retains HAS3 at the plasma membrane, enlarges the cell-surface HA coat, and impairs cell adhesion in an HA-dependent manner [PMID:24509846]. HAS3 assembles into homomeric and HAS1/HAS2 heteromeric complexes via its N-terminal domain in both Golgi and plasma membrane, with HAS3 homomers being the most synthetically active [PMID:25795779], and ongoing HA synthesis maintains HAS3 within plasma membrane protrusions and dorsal ruffles [PMID:26162854, PMID:26448759]. Functionally, HAS3-derived HA regulates extracellular space volume and neuronal excitability—Has3-knockout mice show reduced hippocampal extracellular space and seizure susceptibility [PMID:24790187]—and modulates epithelial junction formation and mitotic spindle orientation [PMID:22159845], cell adhesion, migration and proliferation through HA-receptor and ERK signaling [PMID:26222208], and intercellular communication via extracellular vesicles carrying HA and Indian Hedgehog that activate hedgehog signaling in recipient cells [PMID:31820036]. HAS3 expression is controlled transcriptionally through Sp1-dependent promoter elements [PMID:25843802], retinoic acid receptor signaling [PMID:23748778], and FOSL1 [PMID:38402581], and post-transcriptionally by miR-10b and miR-29a [PMID:31948751].","teleology":[{"year":2013,"claim":"Established that HAS3 is distinguished from other HAS isoenzymes by its ability to synthesize HA efficiently at low substrate concentrations, defining it as a high-efficiency, substrate-sensitive synthase.","evidence":"Transfection of COS-1 cells with human HAS1-3, with UDP-sugar manipulation and HA secretion measurement","pmids":["23303191"],"confidence":"High","gaps":["Does not resolve the structural basis of HAS3's higher substrate affinity","Performed in transfected COS-1 cells, not native tissue"]},{"year":2011,"claim":"Showed that HAS3-driven HA accumulation disrupts epithelial organization, linking the enzyme to junction formation and mitotic spindle orientation.","evidence":"Stable GFP-HAS3 overexpression in MDCK cells, 3D cyst culture, junction and spindle imaging","pmids":["22159845"],"confidence":"Medium","gaps":["Based on overexpression; endogenous contribution unclear","Mechanism linking HA coat to spindle orientation not defined"]},{"year":2014,"claim":"Identified Rab10 as the GTPase controlling HAS3 endocytic recycling, establishing trafficking as a determinant of surface HA synthesis and HA-dependent adhesion.","evidence":"Reciprocal Co-IP from endosomal fractions, Rab10 siRNA/overexpression, live imaging, adhesion assay with hyaluronidase rescue","pmids":["24509846"],"confidence":"High","gaps":["Direct vs indirect Rab10-HAS3 interaction not distinguished","Single lab"]},{"year":2014,"claim":"Demonstrated in vivo that HAS3 is the major source of hippocampal HA and that its loss reduces extracellular space and provokes epileptiform activity, establishing a physiological role in brain tissue architecture and excitability.","evidence":"Has3-/- knockout mice with iontophoretic ECS measurement, diffusion imaging, slice electrophysiology, osmotic manipulation","pmids":["24790187"],"confidence":"High","gaps":["Molecular link between ECS volume and neuronal excitability not fully resolved","Does not address HAS3 function outside the hippocampus"]},{"year":2015,"claim":"Resolved HAS3 oligomerization, showing it forms homo- and heteromeric complexes with HAS1/HAS2 via its N-terminal domain, with functional consequences for HA output.","evidence":"FRET in live cells, proximity ligation assay on endogenous HAS, C-terminal deletion mapping","pmids":["25795779"],"confidence":"High","gaps":["Stoichiometry of complexes unknown","No structural model of the assembly interface"]},{"year":2015,"claim":"Established that ongoing HA synthesis physically retains HAS3 in plasma membrane protrusions and dorsal ruffles, coupling enzymatic activity to membrane morphology.","evidence":"GFP-HAS3 overexpression with hyaluronidase rescue, cytoskeletal marker immunostaining, and CLEM","pmids":["26162854","26448759"],"confidence":"Medium","gaps":["Based on overexpression","Functional role of protrusion localization not defined"]},{"year":2015,"claim":"Connected HAS3-driven HA coat expansion to suppression of melanoma adhesion, migration and proliferation through both HA-receptor-dependent and ERK-dependent routes.","evidence":"Inducible HAS3 expression in MV3 cells with hyaluronidase/oligosaccharide blocking, cell-cycle analysis, ERK1/2 western blot","pmids":["26222208"],"confidence":"Medium","gaps":["Mechanism of receptor-independent proliferation arrest unresolved","Single cell line"]},{"year":2015,"claim":"Defined the HAS3 core promoter architecture, identifying functional Sp1 sites and an MTE that drive transcription in the absence of a TATA box.","evidence":"5' RACE, deletion analysis, site-directed mutagenesis of Sp1/MTE sites, luciferase reporters","pmids":["25843802"],"confidence":"Medium","gaps":["Upstream signals converging on Sp1 not identified","Tissue specificity of promoter variants unknown"]},{"year":2013,"claim":"Linked retinoic acid receptor signaling to HAS3 induction, showing carotenoid metabolites can upregulate HAS3 and HA synthesis in keratinocytes.","evidence":"RAR antagonist and retinal dehydrogenase inhibitor treatment, RARE reporter, qPCR in human keratinocytes","pmids":["23748778"],"confidence":"Medium","gaps":["Direct RAR binding to the HAS3 locus not shown","Identity of active metabolite inferred"]},{"year":2016,"claim":"Showed that cytosolic UDP-GlcNAc and O-GlcNAcylation control HAS3 surface residence by modulating endocytosis and lysosomal decay, coupling metabolic state to HA synthesis and vesicular shedding.","evidence":"Live-cell imaging, endocytosis assays, O-GlcNAc pharmacology, EV isolation in HAS3-expressing cells","pmids":["26883802"],"confidence":"High","gaps":["O-GlcNAc modification site on HAS3 not mapped","Single lab"]},{"year":2019,"claim":"Revealed that HAS3-loaded extracellular vesicles carry IHH and activate hedgehog signaling in recipient cells via CD44-HA binding, establishing HAS3 in intercellular signaling and pro-tumorigenic communication.","evidence":"GFP-HAS3 melanoma EV isolation, CD44 blocking, hedgehog reporter, c-Myc/claspin western blot, IHH proteomics","pmids":["31820036"],"confidence":"Medium","gaps":["Mechanism of IHH loading into EVs unknown","Overexpression-based system"]},{"year":2020,"claim":"Identified miR-10b and miR-29a as direct post-transcriptional repressors of HAS3, linking its regulation to prostate cancer neuroendocrine transdifferentiation.","evidence":"3'UTR luciferase reporters, western blot, qRT-PCR, proliferation/migration assays in LNCaP cells","pmids":["31948751"],"confidence":"Medium","gaps":["Context-dependent direction of HAS3's effect on proliferation/colony formation unresolved","Single cell line"]},{"year":2022,"claim":"Placed HAS3 in airway progenitor fate decisions, showing its delayed upregulation promotes goblet cell differentiation during allergic inflammation.","evidence":"IL-4 stimulation of nasal epithelial cells, 4-methylumbelliferone inhibition, murine allergic rhinitis model, cell-type-resolved expression","pmids":["35679095"],"confidence":"Medium","gaps":["4-MU inhibits HA synthesis broadly, not HAS3-specifically","HAS3-specific genetic perturbation not performed"]},{"year":2024,"claim":"Established FOSL1 as a transcriptional activator of HAS3 controlling HA-dependent cancer stem cell properties, identifying a druggable upstream regulator.","evidence":"FOSL1 knockdown/overexpression, HAS3 mRNA/protein, HA ELISA, sphere formation, in vivo tumor-initiating assays in HNSCC","pmids":["38402581"],"confidence":"Medium","gaps":["Direct FOSL1 binding to HAS3 promoter only implied","Single tumor type"]},{"year":null,"claim":"The molecular basis of HAS3 substrate specificity, the precise O-GlcNAc modification sites controlling its trafficking, and the structural organization of its homo/heteromeric complexes remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of HAS3 or its complexes","O-GlcNAc and trafficking signal residues unmapped","Direct vs indirect Rab10 interaction unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2,3,4]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[1,2]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,7]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[1,2,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,11]}],"complexes":["HAS3 homomer","HAS1/HAS2/HAS3 heteromeric synthase complex"],"partners":["HAS1","HAS2","RAB10","CD44"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00219","full_name":"Hyaluronan synthase 3","aliases":["Hyaluronate synthase 3","Hyaluronic acid synthase 3","HA synthase 3"],"length_aa":553,"mass_kda":63.0,"function":"Catalyzes the addition of GlcNAc or GlcUA monosaccharides to the nascent hyaluronan polymer. Therefore, it is essential to hyaluronan synthesis a major component of most extracellular matrices that has a structural role in tissues architectures and regulates cell adhesion, migration and differentiation. This is one of three isoenzymes responsible for cellular hyaluronan synthesis","subcellular_location":"Cell membrane; Golgi apparatus membrane; Golgi apparatus, trans-Golgi network membrane; Early endosome","url":"https://www.uniprot.org/uniprotkb/O00219/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HAS3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HAS3","total_profiled":1310},"omim":[{"mim_id":"614353","title":"HAS2 ANTISENSE RNA 1; HAS2AS1","url":"https://www.omim.org/entry/614353"},{"mim_id":"607456","title":"UTP4 SMALL SUBUNIT PROCESSOME COMPONENT; UTP4","url":"https://www.omim.org/entry/607456"},{"mim_id":"602428","title":"HYALURONAN SYNTHASE 3; HAS3","url":"https://www.omim.org/entry/602428"},{"mim_id":"601636","title":"HYALURONAN SYNTHASE 2; HAS2","url":"https://www.omim.org/entry/601636"},{"mim_id":"601463","title":"HYALURONAN SYNTHASE 1; HAS1","url":"https://www.omim.org/entry/601463"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Microtubules","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":32.1},{"tissue":"urinary bladder","ntpm":86.6}],"url":"https://www.proteinatlas.org/search/HAS3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O00219","domains":[{"cath_id":"-","chopping":"1-84_219-553","consensus_level":"medium","plddt":90.507,"start":1,"end":553}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00219","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00219-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00219-F1-predicted_aligned_error_v6.png","plddt_mean":90.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HAS3","jax_strain_url":"https://www.jax.org/strain/search?query=HAS3"},"sequence":{"accession":"O00219","fasta_url":"https://rest.uniprot.org/uniprotkb/O00219.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00219/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00219"}},"corpus_meta":[{"pmid":"12787132","id":"PMC_12787132","title":"EGF upregulates, whereas TGF-beta downregulates, the hyaluronan synthases Has2 and Has3 in organotypic keratinocyte cultures: correlations with epidermal proliferation and differentiation.","date":"2003","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12787132","citation_count":139,"is_preprint":false},{"pmid":"24790187","id":"PMC_24790187","title":"Hyaluronan deficiency due to Has3 knock-out causes altered neuronal activity and seizures via reduction in brain extracellular space.","date":"2014","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24790187","citation_count":125,"is_preprint":false},{"pmid":"23303191","id":"PMC_23303191","title":"Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23303191","citation_count":97,"is_preprint":false},{"pmid":"26883802","id":"PMC_26883802","title":"UDP-sugar substrates of HAS3 regulate its O-GlcNAcylation, intracellular traffic, extracellular shedding and correlate with melanoma progression.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/26883802","citation_count":51,"is_preprint":false},{"pmid":"24406795","id":"PMC_24406795","title":"Extensive CD44-dependent hyaluronan coats on human bone marrow-derived mesenchymal stem cells produced by hyaluronan synthases HAS1, HAS2 and HAS3.","date":"2014","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24406795","citation_count":50,"is_preprint":false},{"pmid":"25795779","id":"PMC_25795779","title":"Fluorescence resonance energy transfer (FRET) and proximity ligation assays reveal functionally relevant homo- and heteromeric complexes among hyaluronan synthases HAS1, HAS2, and HAS3.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25795779","citation_count":36,"is_preprint":false},{"pmid":"29693123","id":"PMC_29693123","title":"miR‑29a‑3p represses proliferation and metastasis of gastric cancer cells via attenuating HAS3 levels.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29693123","citation_count":27,"is_preprint":false},{"pmid":"24509846","id":"PMC_24509846","title":"Rab10-mediated endocytosis of the hyaluronan synthase HAS3 regulates hyaluronan synthesis and cell adhesion to collagen.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24509846","citation_count":26,"is_preprint":false},{"pmid":"26162854","id":"PMC_26162854","title":"Cell protrusions induced by hyaluronan synthase 3 (HAS3) resemble mesothelial microvilli and share cytoskeletal features of filopodia.","date":"2015","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26162854","citation_count":26,"is_preprint":false},{"pmid":"16773198","id":"PMC_16773198","title":"HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells.","date":"2006","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16773198","citation_count":26,"is_preprint":false},{"pmid":"31820036","id":"PMC_31820036","title":"HAS3-induced extracellular vesicles from melanoma cells stimulate IHH mediated c-Myc upregulation via the hedgehog signaling pathway in target cells.","date":"2019","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/31820036","citation_count":23,"is_preprint":false},{"pmid":"22159845","id":"PMC_22159845","title":"HAS3-induced accumulation of hyaluronan in 3D MDCK cultures results in mitotic spindle misorientation and disturbed organization of epithelium.","date":"2011","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22159845","citation_count":22,"is_preprint":false},{"pmid":"23748778","id":"PMC_23748778","title":"Lutein, a nonprovitamin A, activates the retinoic acid receptor to induce HAS3-dependent hyaluronan synthesis in keratinocytes.","date":"2013","source":"Bioscience, biotechnology, and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23748778","citation_count":21,"is_preprint":false},{"pmid":"26222208","id":"PMC_26222208","title":"Hyaluronan synthase 3 (HAS3) overexpression downregulates MV3 melanoma cell proliferation, migration and adhesion.","date":"2015","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26222208","citation_count":19,"is_preprint":false},{"pmid":"36581895","id":"PMC_36581895","title":"Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma.","date":"2022","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/36581895","citation_count":18,"is_preprint":false},{"pmid":"25843802","id":"PMC_25843802","title":"Identification and analysis of the promoter region of the human HAS3 gene.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25843802","citation_count":14,"is_preprint":false},{"pmid":"31948751","id":"PMC_31948751","title":"The regulation of HAS3 by miR-10b and miR-29a in neuroendocrine transdifferentiated LNCaP prostate cancer cells.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31948751","citation_count":12,"is_preprint":false},{"pmid":"26448759","id":"PMC_26448759","title":"Correlative Light and Electron Microscopy Reveals the HAS3-Induced Dorsal Plasma Membrane Ruffles.","date":"2015","source":"International journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26448759","citation_count":10,"is_preprint":false},{"pmid":"35679095","id":"PMC_35679095","title":"Cell-Type-Specific Expression of Hyaluronan Synthases HAS2 and HAS3 Promotes Goblet Cell Hyperplasia in Allergic Airway Inflammation.","date":"2022","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35679095","citation_count":8,"is_preprint":false},{"pmid":"38402581","id":"PMC_38402581","title":"Melatonin inhibits the stemness of head and neck squamous cell carcinoma by modulating HA synthesis via the FOSL1/HAS3 axis.","date":"2024","source":"Journal of pineal research","url":"https://pubmed.ncbi.nlm.nih.gov/38402581","citation_count":8,"is_preprint":false},{"pmid":"33499323","id":"PMC_33499323","title":"C1q-HA Matrix Regulates the Local Synthesis of Hyaluronan in Malignant Pleural Mesothelioma by Modulating HAS3 Expression.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33499323","citation_count":8,"is_preprint":false},{"pmid":"25427133","id":"PMC_25427133","title":"Localisation and endocrine control of hyaluronan synthase (HAS) 2, HAS3 and CD44 expression in sheep granulosa cells.","date":"2016","source":"Reproduction, fertility, and development","url":"https://pubmed.ncbi.nlm.nih.gov/25427133","citation_count":7,"is_preprint":false},{"pmid":"35569384","id":"PMC_35569384","title":"Microscopic characterization reveals the diversity of EVs secreted by GFP-HAS3 expressing MCF7 cells.","date":"2022","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35569384","citation_count":7,"is_preprint":false},{"pmid":"41851636","id":"PMC_41851636","title":"NFAT1+ microglia promote antiinflammatory polarization and angiogenesis via the HAS3-HA-LYVE1 axis to improve ischemic stroke outcomes.","date":"2026","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/41851636","citation_count":0,"is_preprint":false},{"pmid":"18687209","id":"PMC_18687209","title":"[Construction of eukaryotic expression vector of rat HAS-3 gene and its effects on chemotaxis].","date":"2008","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18687209","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.12.637910","title":"Glucocorticoids modulate expression of perineuronal net component genes and parvalbumin during development of mouse cortical neurons","date":"2025-02-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.12.637910","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15588,"output_tokens":4572,"usd":0.057672,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12740,"output_tokens":4451,"usd":0.087487,"stage2_stop_reason":"end_turn"},"total_usd":0.145159,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"HAS3 produces hyaluronan at high speed even with minimum UDP-sugar substrate content, in contrast to HAS1 (which requires ~10-fold higher UDP-GlcNAc) and HAS2 (intermediate requirement). Transfected HAS3 consumed enough UDP-sugars to reduce their cellular content in COS-1 cells.\",\n      \"method\": \"Transfection of COS-1 cells with human HAS1-3 isoenzymes; glucosamine supplementation and glucose deprivation to manipulate UDP-sugar levels; measurement of hyaluronan secretion and UDP-sugar content\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with substrate manipulation in transfected cells, multiple orthogonal conditions tested, single lab\",\n      \"pmids\": [\"23303191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HAS3 undergoes rapid recycling between the plasma membrane and endosomes, regulated by cytosolic UDP-GlcNAc and UDP-GlcUA levels. UDP-GlcNAc surplus suppresses HAS3 endocytosis and lysosomal decay, retaining HAS3 at the plasma membrane and stimulating hyaluronan synthesis and HAS3 shedding in extracellular vesicles. UDP-GlcNAc concentration also controls the level of O-GlcNAc modification of HAS3; increasing O-GlcNAcylation reproduces the effects of UDP-GlcNAc surplus on HAS3 trafficking, while suppression shows opposite effects.\",\n      \"method\": \"Live-cell fluorescence microscopy, endocytosis assays, O-GlcNAc inhibition/enhancement pharmacology, extracellular vesicle isolation and characterization in HAS3-expressing cells\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (live imaging, pharmacological manipulation, vesicle shedding assays), single lab\",\n      \"pmids\": [\"26883802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Rab10 GTPase controls HAS3 endocytic traffic: Rab10 colocalizes with HAS3 in intracellular vesicles and co-immunoprecipitates with HAS3 from endosomal fractions. Rab10 silencing increases plasma membrane residence of HAS3, resulting in increased HA secretion and enlarged cell-surface HA coat; Rab10 overexpression suppresses HA synthesis. Rab10 silencing blocks retrograde traffic of HAS3 from plasma membrane to early endosomes. The enlarged HA coat impairs cell adhesion to type I collagen (adhesion recovered after hyaluronidase treatment).\",\n      \"method\": \"Co-immunoprecipitation from endosomal fractions, Rab10 siRNA silencing, Rab10 overexpression, live fluorescence microscopy, HA coat measurement, cell adhesion assay with hyaluronidase rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP from endosomes plus gain/loss-of-function with defined cellular phenotype and hyaluronidase rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24509846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HAS3 forms homomeric complexes with itself and heteromeric complexes with HAS1 and HAS2. These complexes are present in both the Golgi apparatus and the plasma membrane. Interaction occurs mainly via the N-terminal 86-amino acid domain, with additional binding sites in the C-terminal region. HAS3 homomers show the highest synthetic activity among HAS homomers. HAS1 transfection reduced HA synthesis driven by HAS2 and HAS3, indicating functional cooperation.\",\n      \"method\": \"FRET in live cells (flow cytometric FRET and acceptor photobleaching FRET microscopy), proximity ligation assay with endogenous HAS antibodies, C-terminal deletion mutants to map interaction domains\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal PLA for endogenous proteins plus FRET with deletion mapping, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"25795779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GFP-HAS3 overexpression induces the formation of long, slender plasma membrane protrusions that are maintained by ongoing hyaluronan synthesis; hyaluronidase digestion causes immediate GFP-HAS3 exit from protrusions and protrusion collapse, indicating that the extracellular hyaluronan chain retains HAS3 in the plasma membrane. These protrusions share cytoskeletal features with filopodia (fascin, Myo10 positive) but do not require substratum attachment.\",\n      \"method\": \"GFP-HAS3 overexpression in MCF-7 cells, live fluorescence microscopy, hyaluronidase treatment, immunostaining of cytoskeletal markers (villin, ezrin, espin, fascin, Myo10), ultrastructural comparison with rat peritoneal mesothelial cells\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — live imaging plus hyaluronidase rescue and cytoskeletal marker analysis, single lab, single study\",\n      \"pmids\": [\"26162854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Correlative light and electron microscopy (CLEM) revealed that GFP-HAS3 localizes to and induces dorsal plasma membrane ruffles, not only elongated protrusions.\",\n      \"method\": \"Correlative light and electron microscopy (CLEM) of GFP-HAS3 expressing cells\",\n      \"journal\": \"International journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct high-resolution structural localization by CLEM, single lab, single method\",\n      \"pmids\": [\"26448759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HAS3 overexpression in MDCK cells causes accumulation of hyaluronan at apical and basolateral membrane domains, impairing cell-cell junction formation and epithelial barrier function. In 3D cyst cultures, HAS3-induced HA accumulation results in aberrant mitotic spindle orientation and multiple small lumina instead of a single lumen.\",\n      \"method\": \"Stable overexpression of GFP-HAS3 in MDCK cells, 3D cyst culture, fluorescence microscopy of cell-cell junctions and mitotic spindles, barrier function assay\",\n      \"journal\": \"Histochemistry and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — defined cellular phenotypes with GFP-HAS3 overexpression in 3D culture, multiple readouts, single lab\",\n      \"pmids\": [\"22159845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Has3 knockout mice show the greatest reduction of HA in the hippocampus among Has knockout models, with a ~40% reduction in extracellular space (ECS) volume specifically in the CA1 stratum pyramidale, increased cell packing, reduced molecular diffusion through ECS, spontaneous epileptiform activity in CA1 pyramidal neurons, and susceptibility to seizures. Osmotic manipulation experiments provided causal evidence linking reduced ECS volume to epileptiform activity.\",\n      \"method\": \"Has3-/- knockout mice; real-time iontophoretic measurement of ECS volume; fluorescent marker diffusion imaging; electrophysiology in brain slices; osmotic manipulation experiments\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal in vivo and ex vivo methods (ECS measurement, electrophysiology, histology, osmotic rescue), well-controlled study\",\n      \"pmids\": [\"24790187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HAS3 overexpression in MV3 melanoma cells expands the cell-surface HA coat and decreases cell adhesion, migration, and proliferation (G1/G0 arrest). Migration inhibition was reversed by hyaluronidase or HA oligosaccharide receptor blocking, indicating HA-receptor-dependent effect. Proliferation inhibition was receptor-independent. HAS3 overexpression decreased ERK1/2 phosphorylation, implicating MAP-kinase signaling.\",\n      \"method\": \"Inducible HAS3 expression in MV3 cells; hyaluronidase treatment and HA oligosaccharide competitive blocking; cell cycle analysis; ERK1/2 phosphorylation by western blot; migration and adhesion assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — loss-of-function/gain-of-function with defined phenotypic readouts and rescue experiments, single lab\",\n      \"pmids\": [\"26222208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lutein (a non-provitamin A carotenoid) activates retinoic acid receptor (RAR) signaling to upregulate HAS3 gene expression and hyaluronan synthesis in human keratinocytes. The RAR antagonist LE540 abolished lutein-dependent hyaluronan synthesis. Citral (retinal dehydrogenase inhibitor) decreased lutein-stimulated synthesis, suggesting lutein metabolites (not lutein itself) act as RAR ligands.\",\n      \"method\": \"RAR antagonist (LE540) treatment, retinal dehydrogenase inhibitor (citral) treatment, RARE-driven reporter assay, qPCR of HAS3 mRNA, HA synthesis measurement in cultured human keratinocytes\",\n      \"journal\": \"Bioscience, biotechnology, and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological pathway dissection with reporter assay, multiple inhibitors tested, single lab\",\n      \"pmids\": [\"23748778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The HAS3 gene promoter lacks a canonical TATA box but contains GC boxes with functional Sp1 binding sites. A proximal Sp1 binding site is essential for robust proximal promoter activity, and a core MTE (motif ten element) is required for basic core promoter activity. Two novel transcriptional variants with distinct transcription start sites were identified.\",\n      \"method\": \"5' RACE, progressive deletion analysis of the 5'-flanking region, site-directed mutagenesis of Sp1 and MTE sites, luciferase reporter assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — site-directed mutagenesis with reporter assays establishing functional promoter elements, single lab\",\n      \"pmids\": [\"25843802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HAS3-overexpressing melanoma cells shed extracellular vesicles (EVs) carrying HAS3, hyaluronan, and IHH (Indian Hedgehog). These EVs bind target cells via CD44-HA interaction and activate the hedgehog signaling cascade in target cells, leading to c-Myc upregulation and increased claspin expression, resulting in enhanced proliferation and epithelial-to-mesenchymal transition.\",\n      \"method\": \"GFP-HAS3 overexpression in metastatic melanoma cells; EV isolation and characterization; CD44-blocking experiments; treatment of recipient keratinocytes and melanoma cells; hedgehog pathway reporter assays; c-Myc and claspin western blot; IHH proteomics identification in EVs\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple orthogonal methods (EV characterization, CD44 blocking, pathway reporters, western blot), single lab\",\n      \"pmids\": [\"31820036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-10b and miR-29a directly repress HAS3 expression by binding its 3'UTR. HAS3 inhibits cell proliferation and migration in LNCaP prostate cancer cells, while increasing colony-forming ability. During neuroendocrine transdifferentiation, miR-10b and miR-29a are induced and HAS3 is repressed.\",\n      \"method\": \"Reporter gene assays (3'UTR luciferase), western blotting, qRT-PCR, cell proliferation and migration assays with HAS3 modulation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — 3'UTR reporter assay plus protein-level validation and functional cellular assays, single lab\",\n      \"pmids\": [\"31948751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FOSL1 transcriptionally regulates HAS3 expression; melatonin suppresses FOSL1 and thereby downregulates HAS3, reducing HA accumulation and inhibiting cancer stem cell properties (CD44 expression, tumor-initiating frequency) in head and neck squamous cell carcinoma.\",\n      \"method\": \"FOSL1 knockdown and overexpression, HAS3 mRNA/protein measurement, HA ELISA, tumor sphere formation assays, in vivo tumor-initiating frequency assay, ChIP or transcription factor binding analysis implied\",\n      \"journal\": \"Journal of pineal research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — gain/loss-of-function for FOSL1 with HAS3 as readout plus in vivo validation, single lab\",\n      \"pmids\": [\"38402581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HAS3 is expressed in airway intermediate progenitor cells (IPCs) and its delayed upregulation (after HAS2) promotes the transition of suprabasal IPCs to a goblet cell fate during IL-4-induced allergic airway inflammation. Inhibition of HA synthesis by 4-methylumbelliferone suppressed IL-4-induced goblet cell hyperplasia.\",\n      \"method\": \"IL-4 stimulation of primary human nasal epithelial cells; HAS2/HAS3 mRNA and protein analysis; 4-methylumbelliferone inhibition; house dust mite murine AR model with MU treatment; cell-type-specific expression analysis\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological inhibition with defined cellular phenotype in vitro and in vivo, cell-type resolved expression, single lab\",\n      \"pmids\": [\"35679095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GFP-HAS3 overexpression in MCF7 breast cancer cells promotes shedding of morphologically diverse extracellular vesicles, as characterized by multiple high-resolution imaging modalities in situ in monolayer and 3D cultures.\",\n      \"method\": \"Stable GFP-HAS3 expression in MCF7 cells; electron microscopy, confocal microscopy, cryo-EM, and other high-resolution imaging of EVs in situ\",\n      \"journal\": \"European journal of cell biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — morphological characterization only, no biochemical or functional mechanistic dissection, single lab\",\n      \"pmids\": [\"35569384\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HAS3 is a plasma membrane-localized hyaluronan synthase that synthesizes hyaluronan from UDP-GlcNAc and UDP-GlcUA with high catalytic efficiency even at low substrate concentrations; it undergoes Rab10-mediated endocytic recycling between the plasma membrane and endosomes, with its surface residence—and thus HA synthesis—controlled by UDP-GlcNAc levels and O-GlcNAcylation; it forms homo- and heteromeric complexes with HAS1/HAS2 primarily via its N-terminal domain; its synthesis product maintains HAS3 in plasma membrane protrusions (filopodia-like structures and dorsal ruffles); it is transcriptionally regulated by EGF/TGF-β, retinoic acid receptor signaling via FOSL1 and Sp1, and post-transcriptionally by miR-29a and miR-10b; and it regulates extracellular space volume in the brain, cell adhesion via ERK signaling, mitotic spindle orientation in epithelia, and intercellular communication through EV shedding carrying IHH to activate hedgehog signaling in recipient cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HAS3 is a plasma membrane hyaluronan synthase that drives extracellular matrix and cell-surface hyaluronan (HA) production, displaying the highest catalytic efficiency among the HAS isoenzymes and synthesizing HA rapidly even at low UDP-sugar substrate concentrations [#0, #3]. Its synthetic output is governed by trafficking: HAS3 cycles rapidly between the plasma membrane and endosomes, and surplus cytosolic UDP-GlcNAc—acting in part through O-GlcNAcylation of HAS3—suppresses its endocytosis and lysosomal turnover, retaining the enzyme at the cell surface to stimulate HA synthesis and HAS3 shedding in extracellular vesicles [#1]. This retrograde endocytic traffic is controlled by the Rab10 GTPase, which binds HAS3 in endosomes; loss of Rab10 retains HAS3 at the plasma membrane, enlarges the cell-surface HA coat, and impairs cell adhesion in an HA-dependent manner [#2]. HAS3 assembles into homomeric and HAS1/HAS2 heteromeric complexes via its N-terminal domain in both Golgi and plasma membrane, with HAS3 homomers being the most synthetically active [#3], and ongoing HA synthesis maintains HAS3 within plasma membrane protrusions and dorsal ruffles [#4, #5]. Functionally, HAS3-derived HA regulates extracellular space volume and neuronal excitability—Has3-knockout mice show reduced hippocampal extracellular space and seizure susceptibility [#7]—and modulates epithelial junction formation and mitotic spindle orientation [#6], cell adhesion, migration and proliferation through HA-receptor and ERK signaling [#8], and intercellular communication via extracellular vesicles carrying HA and Indian Hedgehog that activate hedgehog signaling in recipient cells [#11]. HAS3 expression is controlled transcriptionally through Sp1-dependent promoter elements [#10], retinoic acid receptor signaling [#9], and FOSL1 [#13], and post-transcriptionally by miR-10b and miR-29a [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established that HAS3 is distinguished from other HAS isoenzymes by its ability to synthesize HA efficiently at low substrate concentrations, defining it as a high-efficiency, substrate-sensitive synthase.\",\n      \"evidence\": \"Transfection of COS-1 cells with human HAS1-3, with UDP-sugar manipulation and HA secretion measurement\",\n      \"pmids\": [\"23303191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve the structural basis of HAS3's higher substrate affinity\", \"Performed in transfected COS-1 cells, not native tissue\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed that HAS3-driven HA accumulation disrupts epithelial organization, linking the enzyme to junction formation and mitotic spindle orientation.\",\n      \"evidence\": \"Stable GFP-HAS3 overexpression in MDCK cells, 3D cyst culture, junction and spindle imaging\",\n      \"pmids\": [\"22159845\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Based on overexpression; endogenous contribution unclear\", \"Mechanism linking HA coat to spindle orientation not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified Rab10 as the GTPase controlling HAS3 endocytic recycling, establishing trafficking as a determinant of surface HA synthesis and HA-dependent adhesion.\",\n      \"evidence\": \"Reciprocal Co-IP from endosomal fractions, Rab10 siRNA/overexpression, live imaging, adhesion assay with hyaluronidase rescue\",\n      \"pmids\": [\"24509846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect Rab10-HAS3 interaction not distinguished\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated in vivo that HAS3 is the major source of hippocampal HA and that its loss reduces extracellular space and provokes epileptiform activity, establishing a physiological role in brain tissue architecture and excitability.\",\n      \"evidence\": \"Has3-/- knockout mice with iontophoretic ECS measurement, diffusion imaging, slice electrophysiology, osmotic manipulation\",\n      \"pmids\": [\"24790187\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between ECS volume and neuronal excitability not fully resolved\", \"Does not address HAS3 function outside the hippocampus\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved HAS3 oligomerization, showing it forms homo- and heteromeric complexes with HAS1/HAS2 via its N-terminal domain, with functional consequences for HA output.\",\n      \"evidence\": \"FRET in live cells, proximity ligation assay on endogenous HAS, C-terminal deletion mapping\",\n      \"pmids\": [\"25795779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of complexes unknown\", \"No structural model of the assembly interface\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established that ongoing HA synthesis physically retains HAS3 in plasma membrane protrusions and dorsal ruffles, coupling enzymatic activity to membrane morphology.\",\n      \"evidence\": \"GFP-HAS3 overexpression with hyaluronidase rescue, cytoskeletal marker immunostaining, and CLEM\",\n      \"pmids\": [\"26162854\", \"26448759\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Based on overexpression\", \"Functional role of protrusion localization not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected HAS3-driven HA coat expansion to suppression of melanoma adhesion, migration and proliferation through both HA-receptor-dependent and ERK-dependent routes.\",\n      \"evidence\": \"Inducible HAS3 expression in MV3 cells with hyaluronidase/oligosaccharide blocking, cell-cycle analysis, ERK1/2 western blot\",\n      \"pmids\": [\"26222208\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of receptor-independent proliferation arrest unresolved\", \"Single cell line\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the HAS3 core promoter architecture, identifying functional Sp1 sites and an MTE that drive transcription in the absence of a TATA box.\",\n      \"evidence\": \"5' RACE, deletion analysis, site-directed mutagenesis of Sp1/MTE sites, luciferase reporters\",\n      \"pmids\": [\"25843802\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream signals converging on Sp1 not identified\", \"Tissue specificity of promoter variants unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked retinoic acid receptor signaling to HAS3 induction, showing carotenoid metabolites can upregulate HAS3 and HA synthesis in keratinocytes.\",\n      \"evidence\": \"RAR antagonist and retinal dehydrogenase inhibitor treatment, RARE reporter, qPCR in human keratinocytes\",\n      \"pmids\": [\"23748778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RAR binding to the HAS3 locus not shown\", \"Identity of active metabolite inferred\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed that cytosolic UDP-GlcNAc and O-GlcNAcylation control HAS3 surface residence by modulating endocytosis and lysosomal decay, coupling metabolic state to HA synthesis and vesicular shedding.\",\n      \"evidence\": \"Live-cell imaging, endocytosis assays, O-GlcNAc pharmacology, EV isolation in HAS3-expressing cells\",\n      \"pmids\": [\"26883802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"O-GlcNAc modification site on HAS3 not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed that HAS3-loaded extracellular vesicles carry IHH and activate hedgehog signaling in recipient cells via CD44-HA binding, establishing HAS3 in intercellular signaling and pro-tumorigenic communication.\",\n      \"evidence\": \"GFP-HAS3 melanoma EV isolation, CD44 blocking, hedgehog reporter, c-Myc/claspin western blot, IHH proteomics\",\n      \"pmids\": [\"31820036\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of IHH loading into EVs unknown\", \"Overexpression-based system\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified miR-10b and miR-29a as direct post-transcriptional repressors of HAS3, linking its regulation to prostate cancer neuroendocrine transdifferentiation.\",\n      \"evidence\": \"3'UTR luciferase reporters, western blot, qRT-PCR, proliferation/migration assays in LNCaP cells\",\n      \"pmids\": [\"31948751\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context-dependent direction of HAS3's effect on proliferation/colony formation unresolved\", \"Single cell line\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placed HAS3 in airway progenitor fate decisions, showing its delayed upregulation promotes goblet cell differentiation during allergic inflammation.\",\n      \"evidence\": \"IL-4 stimulation of nasal epithelial cells, 4-methylumbelliferone inhibition, murine allergic rhinitis model, cell-type-resolved expression\",\n      \"pmids\": [\"35679095\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"4-MU inhibits HA synthesis broadly, not HAS3-specifically\", \"HAS3-specific genetic perturbation not performed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established FOSL1 as a transcriptional activator of HAS3 controlling HA-dependent cancer stem cell properties, identifying a druggable upstream regulator.\",\n      \"evidence\": \"FOSL1 knockdown/overexpression, HAS3 mRNA/protein, HA ELISA, sphere formation, in vivo tumor-initiating assays in HNSCC\",\n      \"pmids\": [\"38402581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FOSL1 binding to HAS3 promoter only implied\", \"Single tumor type\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular basis of HAS3 substrate specificity, the precise O-GlcNAc modification sites controlling its trafficking, and the structural organization of its homo/heteromeric complexes remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of HAS3 or its complexes\", \"O-GlcNAc and trafficking signal residues unmapped\", \"Direct vs indirect Rab10 interaction unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"GO:0016757\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2, 3, 4]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 7]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [1, 2, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 11]}\n    ],\n    \"complexes\": [\n      \"HAS3 homomer\",\n      \"HAS1/HAS2/HAS3 heteromeric synthase complex\"\n    ],\n    \"partners\": [\n      \"HAS1\",\n      \"HAS2\",\n      \"RAB10\",\n      \"CD44\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}